Luminal A型乳腺癌新辅助化疗疗效的影响因素分析

doi:10.11904/j.issn.1002-3070.2021.02.006

摘要/Abstract

摘要： 目的探讨影响Luminal A型乳腺癌患者新辅助化疗疗效的相关因素,从而为Luminal A型乳腺癌患者新辅助化疗提供筛选指标,最终为提高新辅助化疗疗效提供参考依据。方法回顾性分析2013年8月23日—2019年11月1日于我院接受术前新辅助化疗并进行手术治疗的Luminal A型乳腺癌患者的临床资料,共计191例患者符合入组标准,采用RECIST1.1评分评估疗效,根据临床有效情况分为CR+PR组和非CR+PR组,分析临床病理特征与疗效的关系以及影响疗效的相关因素。结果 191例Luminal A型乳腺癌患者中临床有效147例(CR+PR组147例)、无效44例(非CR+PR组患者),临床有效率77.0%。腋窝淋巴结降级率达26.8%(45/168),年龄≤50岁、绝经前状态、雌激素受体(ER)＜70%、孕激素受体(PR)＜50%及肿块位于外侧象限与患者临床有效率有关(P＜0.05)。Logistic回归分析结果显示,肿块位置及临床分期是影响Luminal A型乳腺癌患者新辅助化疗后取得临床有效的独立影响因素(P＜0.05)。结论分布于外侧象限及临床分期为Ⅲ期Luminal A型乳腺癌患者新辅助化疗更易取得临床获益,因此Luminal A型乳腺癌患者行新辅助化疗前可进行评估筛选从而提高疗效。

关键词: LuminalA型乳腺癌, 新辅助化疗, 雌激素受体, 病理缓解

Abstract: Objective The aim of this study was to explore the related factors affecting the efficacy of neoadjuvant chemotherapy in patients with Luminal A type breast cancer,so as to provide screening indicators for patients with Luminal A type breast cancer and ultimately provide reference for improving the efficacy of neoadjuvant chemotherapy. Methods The clinical data of patients with Luminal A type breast cancer who received preoperative neoadjuvant chemotherapy and surgical treatment in our hospital from August 23,2013 to November 1,2019 were retrospectively analyzed.A total of 191 patients with type A breast cancer met the inclusion criteria.RECIST1.1 score was used to evaluate the efficacy.According to the clinical efficacy,these patients were divided into the Cr+PR group and non Cr+PR group.The relationship between clinicopathological features,efficacy and the related factors affecting efficacy were analyzed. Results Amongst 191 cases of Luminal A type breast cancer,147 cases were clinically effective(147 in the CR+PR group 44 cases were not clinically effective(44 cases in the non-CR+PR group),and the clinical effective rate of 77.0%.The degradation rate of axillary lymph nodes was 26.8%(45/168).Age ≤50 years old,premenopausal state,estrogen receptor(ER)＜ 70%,progesterone receptor(PR)＜50% and tumor located in the lateral quadrant were associated with the clinical effective rate(P＜0.05).Logistic regression analysis showed that tumor location and clinical stage were independent factors affecting the clinical efficacy of neoadjuvant chemotherapy in patients with Luminal A type breast cancer(P＜0.05). Conclusion Patients with Luminal A type breast cancer distributed in the lateral quadrant and clinical stage Ⅲ are more likely to be clinically effective,and patients with Luminal A type breast cancer can be evaluated and screened before neoadjuvant chemotherapy,so as to improve the curative effect.

Key words: Luminal A type breast cancer;Neoadjuvant chemotherapy;Estrogen receptor;Pathological remission

中图分类号:

R730.5

王健宇, 张显玉, 庞达. Luminal A型乳腺癌新辅助化疗疗效的影响因素分析[J]. 实用肿瘤学杂志, 2021, 35(2): 131-136.

WANG Jianyu, ZHANG Xianyu, PANG Da. Influencing factors of neoadjuvant chemotherapy for Luminal A type breast cancer[J]. Journal of Practical Oncology, 2021, 35(2): 131-136.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2021.02.006

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2021/V35/I2/131

参考文献

1 Desantis CE,Ma J,Gaudet MM,et al.Breast cancer statistics,2019[J].CA Cancer J Clin,2019,69(6):438-451.
2 Ferlay J,Colombet M,Soerjomataram I,et al.Cancer incidence and mortality patterns in Europe:estimates for 40 countries and 25 major cancers in 2018[J].Eur J Cancer,2018,103:356-387.
3 Chen Y,Shi XE,Tian JH,et al.Survival benefit of neoadjuvant chemotherapy for resectable breast cancer:a meta-analysis[J].Medicine(Baltimore),2018,97(20):e10634.
4 Alberro JA,Ballester B,Deulofeu P,et al.Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials[J].Lancet Oncol,2018,19(1): 27-39.
5 中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2019年版)[J].中国癌症杂志,2019,29(8):609-680.
6 Donker M,Straver ME,Wesseling J,et al.Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients:the MARI procedure[J].Ann Surg,2015,261(2):378-382.
7 Von Minckwitz G,Untch M,Blohmer JU,et al.Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes[J].J Clin Oncol,2012,30(15):1796-1804.
8 Haque W,Verma V,Hatch S,et al.Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy[J].Breast Cancer Res Treat,2018,170(3):559-567.
9 Zeidman M,Albert Y-Oller JJ,Meng R,et al.Use of neoadjuvant versus adjuvant chemotherapy for hormone receptor-positive breast cancer: a National Cancer Database(NCDB)study[J].Breast Cancer Res Treat,2020,184(1):203-212.
10 杨文涛,步宏.乳腺癌雌、孕激素受体免疫组织化学检测指南[J].中华病理学杂志,2015,44(4):237-239.
11 Prat A,Cheang MC,Martín M,et al.Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined Luminal A breast cancer[J].J Clin Oncol,2013,31(2):203-209.
12 《乳腺癌her2检测指南(版)》编写组.乳腺癌HER2检测指南(2019版)[J].中华病理学杂志,2019,48(3):169-175.
13 Jain P,Doval DC,Batra U,et al.Ki-67 labeling index as a predictor of response to neoadjuvant chemotherapy in breast cancer[J].Jpn J Clin Oncol,2019,49(4):329-338.
14 Li Q,Liu J,Jiang Z,et al.CSCO breast cancer guideline:precise,economical and oriental[J].Sci China Life Sci,2020,63(9):1-3.
15 Meattini I,Bicchierai G,Saieva C,et al.Impact of molecular subtypes classification concordance between preoperative core needle biopsy and surgical specimen on early breast cancer management:Single-institution experience and review of published literature[J].Eur J Surg Oncol,2017,43(4):642-648.
16 Watanabe H,Okada M,Kaji Y,et al.New response evaluation criteria in solid tumours-revised RECIST guideline(version 1.1)[J].Gan To Kagaku Ryoho,2009,36(13):2495-2501.
17 Hancock MJ.Appraisal of Clinical Practice Guideline:Early and locally advanced breast cancer:diagnosis and management.NICE guideline[NG101][J].J Physiother,2019,65(1):57.
18 Luangdilok S,Samarnthai N,Korphaisarn K.Association between pathological complete response and outcome following neoadjuvant chemotherapy in locally advanced breast cancer patients[J].J Breast Cancer,2014,17(4):376-385.
19 Ryu YJ,Kang SJ,Cho JS,et al.Lymphovascular invasion can be better than pathologic complete response to predict prognosis in breast cancer treated with neoadjuvant chemotherapy[J].Medicine(Baltimore),2018,97(30):e11647.
20 Burstein HJ,Curigliano G,Loibl S,et al.Estimating the benefits of therapy for early-stage breast cancer:the St.Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019[J].Ann Oncol,2019,30(10):1541-1557.
21 Curigliano G,Burstein HJ,Winer EP,et al.De-escalating and escalating treatments for early-stage breast cancer:the St.gallen international expert consensus conference on the primary therapy of early breast cancer 2017[J].Ann Oncol,2017,28(8):1700-1712.
22 Yang Y,Liu J,Peng M,et al.Introduction of a multicenter online database for non-metastatic breast cancer in China[J].Sci China Life Sci,2020,63(9):1-4.
23 Fredholm H,Magnusson K,Lindström LS,et al.Long-term outcome in young women with breast cancer:a population-based study[J].Breast Cancer Res Treat,2016,160(1):131-143.
24 Fredholm H,Magnusson K,Lindström LS,et al.Breast cancer in young women and prognosis:how important are proliferation markers?[J].Eur J Cancer,2017,84:278-289.
25 Zhang Z,Wang J,Skinner KA,et al.Pathological features and clinical outcomes of breast cancer according to levels of oestrogen receptor expression[J].Histopathology,2014,65(4):508-516.
26 Raphael J,Gandhi S,Li N,et al.The role of quantitative estrogen receptor status in predicting tumor response at surgery in breast cancer patients treated with neoadjuvant chemotherapy[J].Breast Cancer Res Treat,2017,164(2):285-294.
27 Yamamoto Y,Yamamoto-Ibusuki M,Iwase H.Menopausal status should be taken into consideration for patients with Luminal A breast cancer in terms of the effect of differential biology on prognosis[J].J Clin Oncol,2013,31(19):2516.
28 Brandão M,Pondé N,Piccart-Gebhart M.Mammaprint?:a comprehensive review[J].Future Oncol,2019,15(2):207-224.
29 Kunst NR,Alarid-Escudero F,Paltiel AD,et al.A value of information analysis of research on the 21-Gene assay for breast cancer management[J].Value Health,2019,22(10):1102-1110.
30 Yang J,Tang S,Zhou Y,et al.Prognostic implication of the primary tumor location in early-stage breast cancer:focus on lower inner zone[J].Breast Cancer,2018,25(1):100-107.

[1]	刘红, 鲁海玲, 蔡莉. 影像学预测乳腺癌患者预后及新辅助化疗反应的研究进展[J]. 实用肿瘤学杂志, 2020, 34(6): 535-539.
[2]	谢贤鑫, 韦军, 邱佳鑫, 王聪, 姜大庆. 乳腺癌新辅助化疗残余肿瘤组织病理信息与预后分析[J]. 实用肿瘤学杂志, 2020, 34(3): 225-231.
[3]	黎玉娇, 尚乃舰. 影像学评估乳腺癌新辅助化疗反应的研究进展[J]. 实用肿瘤学杂志, 2018, 32(1): 63-67.
[4]	王笑笑, 华腾, 汪宏波. 雌激素受体相关受体γ在肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(1): 87-91.
[5]	于飞, 胡晶(综述), 陈雪松(审校). 乳腺癌他莫昔芬耐药机制的研究进展[J]. 实用肿瘤学杂志, 2017, 31(2): 160-164.
[6]	陈力, 张玉新, 左艳娇, 马菲, 宋洪江, 薛英威. SOX和XELOX在进展期胃癌新辅助化疗中的临床疗效比较[J]. 实用肿瘤学杂志, 2017, 31(1): 23-30.
[7]	戴猛, 李锐, 刘贵庭, 梁金龙, 冯金发, 徐善勇. 新辅助化疗后保留乳房手术治疗进展期乳腺癌可行性分析[J]. 实用肿瘤学杂志, 2016, 30(2): 109-113.
[8]	巴志昌, 王欣欣, 崔万辉, 国飞, 张修石. MRI弥散加权成像对宫颈癌新辅助化疗评估的应用价值[J]. 实用肿瘤学杂志, 2015, 29(6): 518-522.
[9]	吕付龙,王泽涛,王劲松. RASSF1A及其甲基化与乳腺癌的关系[J]. 实用肿瘤学杂志, 2015, 29(4): 372-375.
[10]	朱宏, 朱莉, 韩世愈, 方芳, 于洋. 磁共振弥散加权成像对宫颈癌新辅助化疗后无进展生存期的预测价值[J]. 实用肿瘤学杂志, 2014, 28(6): 519-523.
[11]	宁四清, 詹波涛, 徐海声. TNP方案在头颈部鳞状细胞癌中的疗效探讨[J]. 实用肿瘤学杂志, 2014, 28(6): 540-544.
[12]	宋雨霖综述, 王晶审校. 卵巢癌术前新辅助化疗筛选与评估的展望[J]. 实用肿瘤学杂志, 2014, 28(6): 553-556.
[13]	马荣, 陈曦海, 耿晓星, 刘爽, 张恒. 术前同期放化疗对局部晚期宫颈癌近期疗效的综合评价[J]. 实用肿瘤学杂志, 2012, 26(4): 314-318.
[14]	滕冲, 宋晓薇, 蔡莉. Ki-67在乳腺癌新辅助化疗中的作用及临床意义[J]. 实用肿瘤学杂志, 2012, 26(2): 188-192.
[15]	刘扬, 庞达. 乳腺癌新辅助化疗前后Ki-67、HER-2、ER和PR的变化与临床缓解率的关系[J]. 实用肿瘤学杂志, 2011, 25(5): 442-445.